Company

company Introduction
introduction
Company introduction

Products
Product Details

ViroMed. Co., Ltd. PG102

Botanical functional food product made from the extract of hardy kiwi
and approved by KFDA for functional claim. May help improve immune
hypersensitivity.

Botanical functional food product made from the extract of 4 different herbs
HX106 and approved by KFDA for functional claim. May help improve working
ViroMed Co., Ltd. (ViroMed) is a leading memory.
biopharmaceutical company and a leader in
DNA based gene therapy with a focus on the HX811
Botanical functional food product made from the extract of 10 different
herbs that may improve joint health.
development of innovative drugs.
ViroMed was established in 1996 and is headquartered in Seoul, Korea R&D Pipeline
with a US presence in Atlanta. ViroMed has assembled a diverse, but
technologically and conceptually linked, pipeline of innovative thera- Licensed
Pipeline Description DS PC PI PII PIII NDA MKT
peutics in the areas of cardiovascular and neurological diseases, can- Territory
cers, and immune disorders, with 7 projects in clinical stages in the US, DNA based gene therapy target-
VM202-DPN
Korea, and China. ViroMed has successfully completed two separate ing diabetic peripheral neuropa- ○ Korea
(US) thy
phase II clinical studies for diabetic peripheral neuropathy and critical
limb ischemia (an extreme form of peripheral artery disease: PAD) in DNA based gene therapy
the US and Korea and received approval from the US FDA to initiate VM202-PAD targeting chronic non- Korea,
(US, China) healing ischemic foot ulcer in
○ China
phase III study. A phase I/II clinical study for amyotrophic lateral sclero-
sis in the US has also been completed. In China, a phase III clinical trial diabetes patients
is underway for chemotherapy-induced thrombocytopenia. ViroMed is DNA based gene therapy
VM202-ALS
also running a botanical therapeutics and functional food programs (US)
targeting amyotrophic lateral ○ Korea
with one prescription drug for osteoarthritis and three functional food sclerosis
products already in Korean market. DNA based gene therapy
CEO VM202-CAD
(Korea)
targeting coronary artery ○ Korea
Mr. Yong Soo Kim disease
Location Therapeutic cancer vaccine
5th Fl. Bldg. 203 Seoul
VM206 (Korea) targeting Her2 expressing ○ Korea
National University
Gwanak-ro, Gwanak-gu, Seoul, breast cancer
151-747 Recombinant IL-11 protein
Republic of Korea VM501 (China) targeting chemotherapy ○ China
Homepage induced thrombocytopenia
http://viromed.co.kr/kor/index_
intro.html

62 63